Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Retinopathy of Prematurity Ophthalmologic Approach Clinical Presentation

  • Author: Mounir Bashour, MD, PhD, CM, FRCSC, FACS; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Mar 21, 2016
 

History

In 1984, a committee consisting of 23 ophthalmologists from 11 countries formed the International Classification of Retinopathy of Prematurity (ICROP). This new classification system demarcated the location of the disease into zones of the retina (1, 2, and 3), the extent of the disease based on the clock hours (1-12), and the severity of the disease into stages (0-5).

In obtaining a history for a premature infant, note the following:

  • Gestational age at birth, especially if younger than 32 weeks' gestation
  • Birth weight of less than 1500 g, especially less than 1250 grams
  • Other possible risk factors (eg, supplemental oxygen, hypoxemia, hypercarbia, concurrent illness)
Next

Physical

See the image below.

Retinopathy of prematurity consultation form and f Retinopathy of prematurity consultation form and fundus drawing.

ROP is categorized in zones, with stages depicting the severity of the disease. The smaller and younger the infant at birth, the more likely the disease will involve the central zones with advanced stages.

ROP is categorized by the lowest zone and the highest stage observed in each eye.

Zone 1

Zone 1 is the most labile.

The center of zone 1 is the optic nerve. It extends twice the distance from the optic nerve to the macula in a circle. Using a 28-diopter lens, if any portion of the optic nerve is in the same view as the ridge of ROP, that is considered zone 1

Any disease in zone 1 (even stage 0, immature) is critical and must be monitored closely. Zone 1 does not follow the ICROP rules. The area is very small and changes can occur very quickly, sometimes within days. The hallmark of the disease worsening is not the presence of neovascularization (as in other zones, as specified by the ICROP) but is by the increasing dilation and tortuosity of the vessels. The vascularized retina seems to rise (like a soufflé) probably because of the increased arteriovenous shunting. Many ROP experts feel that any disease in zone 1, and certainly any plus disease, requires treatment.

Zone 2

Zone 2 is a circle surrounding the zone 1 circle with the nasal ora serrata as its nasal border.

The disease may progress quickly but usually there are warning signs that predate the threshold by 1-2 weeks, as follows: (1) The ridge shows signs of vascular arcading (increased branching); this is usually a sign that the disease is starting to become aggressive. (2) Increasing vascular dilation and tortuosity is present. (3) A "hot dog" on the ridge is seen; this is a thickened vascular ridge that may not show the typical fronds of neovascularization. Rather the demarcation of vascularized and nonvascular retina is a thickened red 3-dimensional roll. This usually is seen in posterior zone 2 (borders zone 1) and is a poor prognostic indicator. (4) The Cryotherapy for Retinopathy of Prematurity Cooperative Group (CRYO-ROP) study described threshold disease as 5 contiguous or 8 noncontiguous hours of neovascularization (stage 3) with plus disease in zone 1 or 2. Of threshold eyes left untreated, 50% would develop adverse structural outcomes (eg, retinal detachment) 12 months after randomization.

Zone 3

Zone 3 is the crescent that the circle of zone 2 did not encompass temporally.

Aggressive disease rarely is seen in this zone. Typically, this is slowly vascularizing and requires evaluations every few weeks.

Many infants show inactive disease in zone 3 with a demarcation line and nonvascularized retina. This has been noted in toddlers and can be considered cicatricial peripheral disease. No ill sequelae are known to occur from this ridge.

Stage 0

This is the mildest form of ROP. It is immature retinal vasculature. No clear demarcation of vascularized and nonvascularized retina is present. Only a suggestion of the border is noted on examination.

  • In zone 1, this may appear as a vitreous haze, with the optic nerve as the only landmark. Weekly examinations should be performed.
  • In zone 2, bimonthly examinations should be performed.
  • In zone 3, examination every 3-4 weeks should be sufficient.

Stage 1

A fine, thin demarcation line between the vascular and avascular region is present. This line has no height and no thickness.

  • In zone 1, this should appear as a flat, thin line (usually nasally first). No elevation from the avascular retina should be present. The retinal vessels should be smooth, thin, and supple. Weekly examinations should be performed.
  • In zone 2, bimonthly examinations should be performed.
  • In zone 3, examination every 2-3 weeks should be sufficient.

Stage 2

A broad, thick ridge clearly separates the vascular from the avascular retina.

  • In zone 1, if there is any hint of pink or red in the ridge, this is an ominous sign. If there is any vessel engorgement, the disease should be considered threshold and treatment commenced within 72 hours.
  • In zone 2, if there are no vascular changes and the ridge has no engorgement, the eye should be examined within 2 weeks. Prethreshold is defined as stage 2 with plus disease.
  • In zone 3, examination every 2-3 weeks should be sufficient, unless of course there is any vascular tortuosity or straightening of the vascular arcades.

Stage 3

The extraretinal fibrovascular proliferation (neovascularization) may be present on the ridge, on the posterior surface of the ridge or anteriorly toward the vitreous cavity. The neovascularization gives the ridge a velvety appearance, a ragged border.

  • In zone 1, if there is any neovascularization, it is serious and requires treatment.
  • In zone 2, prethreshold is defined as stage 3 without plus disease, or stage 3 with less than 5 contiguous or 8 noncontiguous hours. Threshold is stage 3 with at least 5 contiguous or 8 noncontiguous hours and plus disease.
  • In zone 3, examination every 2-3 weeks should be sufficient, unless there is any vascular tortuosity or straightening of the vascular arcades.

Stage 4

This stage is a subtotal retinal detachment beginning at the ridge. The retina is pulled anteriorly into the vitreous by the fibrovascular ridge.

  • Stage 4A does not involve the fovea.
  • Stage 4B involves the fovea.

Stage 5

This stage is a total retinal detachment in the shape of a funnel.

  • Stage 5A is an open funnel.
  • Stage 5B is a closed funnel.

Plus disease is defined as arteriolar tortuosity and venous engorgement of the posterior pole, iris vascular engorgement, pupillary rigidity, and vitreous haze, which are part of the subclassification given to the above stages. The presence of plus disease is an ominous sign.

Pre-plus disease is defined as vascular abnormalities of the posterior pole that are insufficient for the diagnosis of plus disease but that demonstrate more arteriolar tortuosity and more venular dilatation than normal. Signs of pre-plus disease early in the course of ROP were shown to be strongly associated with development of severe ROP that required laser treatment. The diagnosis of pre-plus disease adds prognostic value beyond that already known with birth weight, gestational age, ROP zone, and ROP stage.[10]

Other terms mentioned with ROP include the following:

  • Popcorn: Regressed neovascularization seen anterior to the internal limiting membrane. This is a cicatricial change and usually regresses completely over several weeks.
  • Hot dog: A "red hot" active ridge, probably the site of increasing vascular channels. This is a critical hot area of activity. If noted on zone 1 or 2, this is an ominous sign. This area may regress with cicatrix floating in the vitreous cavity and nonpatent ghost vessels still visibly attached to the retina (a second ridge would clearly be identified anterior to this cicatrix). In less fortunate eyes, this area may be the site of a true retinal detachment (no advancing ridge would be visible and the vessels would not be ghostly but engorged).
  • Rush disease: A very rapidly progressive subtype of ROP is called rush disease. If plus disease is accompanied by vascularization ending in zone 1 or in very posterior zone 2, the risk of rush disease is significant.
Previous
Next

Causes

ROP is a disease of premature infants. All babies less than 1500 g birth weight or younger than 32 weeks' gestational age at birth are at risk of developing ROP.

Tolsma et al found that late neonatal bacteremia appears to be an independent risk factor for prethreshold/threshold ROP and plus disease. The study also found that presumed late bacteremia was associated with prethreshold/threshold ROP.[11]

Previous
 
 
Contributor Information and Disclosures
Author

Mounir Bashour, MD, PhD, CM, FRCSC, FACS Assistant Professor of Ophthalmology, McGill University Faculty of Medicine; Clinical Assistant Professor of Ophthalmology, Sherbrooke University; Medical Director, Cornea Laser and Lasik MD

Mounir Bashour, MD, PhD, CM, FRCSC, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American College of International Physicians, American College of Surgeons, American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Mechanical Engineers, American Society of Ophthalmic Plastic and Reconstructive Surgery, Biomedical Engineering Society, Canadian Medical Association, Canadian Ophthalmological Society, Contact Lens Association of Ophthalmologists, International College of Surgeons US Section, Ontario Medical Association, Quebec Medical Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Coauthor(s)

C Corina Gerontis, MD Consulting Staff, Departments of Pediatrics and Ophthalmology, Schneider Children's Hospital/Long Island Jewish Medical Center

C Corina Gerontis, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Medical Association

Disclosure: Nothing to disclose.

Johanne Menassa, MD Staff Physician, Department of Ophthalmology, University of Laval Hospital, Quebec City

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, Club Jules Gonin

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

V Al Pakalnis, MD, PhD Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, South Carolina Medical Association

Disclosure: Nothing to disclose.

References
  1. American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013 Jan. 131(1):189-95. [Medline]. [Full Text].

  2. Terry TL. Extreme prematurity and fibroplastic overgrowth of persistent vascular sheath behind each crystalline lens I. Preliminary report. Am J Ophthalmol. 1942. 25:203-4.

  3. Campbell K. Intensive oxygen therapy as a possible cause for retrolental fibroplasia. A clinical approach. Med J Austr. 1951. 2:48-50.

  4. Kretzer FL, Hittner HM. Retinopathy of prematurity: clinical implications of retinal development. Arch Dis Child. 1988 Oct. 63(10 Spec No):1151-67. [Medline].

  5. Ashton N. Oxygen and the retinal blood vessels. Trans Ophthalmol Soc U K. 1980 Sep. 100(3):359-62. [Medline].

  6. Csak K, Szabo V, Szabo A, et al. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci. 2006 Jan 1. 11:908-20. [Medline].

  7. Fielder AR, Shaw DE, Robinson J, et al. Natural history of retinopathy of prematurity: a prospective study. Eye. 1992. 6 (Pt 3):233-42. [Medline].

  8. Varughese S, Gilbert C, Pieper C, et al. Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol. 2008 Jul. 92(7):879-82. [Medline].

  9. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991 Nov. 98(11):1628-40. [Medline].

  10. Wallace DK, Freedman SF, Hartnett ME, Quinn GE. Predictive Value of Pre-plus Disease in Retinopathy of Prematurity. Arch Ophthalmol. 2011 May. 129(5):591-6. [Medline].

  11. Tolsma KW, Allred EN, Chen ML, et al. Neonatal bacteremia and retinopathy of prematurity: the ELGAN study. Arch Ophthalmol. 2011 Dec. 129(12):1555-63. [Medline].

  12. Melville N. Fluorescein Angiography Details Vasculature in ROP. Medscape Medical News. Available at http://www.medscape.com/viewarticle/823289. Accessed: April 14, 2014.

  13. American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2014: Abstract 10. Presented April 3, 2014.

  14. Lajoie A, Koreen S, Wang L, et al. Retinopathy of prematurity management using single-image vs multiple-image telemedicine examinations. Am J Ophthalmol. 2008 Aug. 146(2):298-309. [Medline].

  15. Geloneck MM, Chuang AZ, Clark WL, et al, for the BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014 Aug 7. [Medline].

  16. Boggs W. Lower risk of very high myopia with vevacizumab for retinopathy of prematurity. Reuters Health Information. August 14, 2014. [Full Text].

  17. Roach L. Laser treatment halts retinopathy in extreme prematurity. Medscape Medical News. April 4, 2013. [Full Text].

  18. Gunn DJ, Cartwright DW, Yuen SA, Gole GA. Treatment of retinopathy of prematurity in extremely premature infants over an 18-year period. Clin Experiment Ophthalmol. 2013 Mar. 41(2):159-66. [Medline].

  19. Harrison P. Lens Clarity Excellent With Vitrectomy in Early Retinopathy. Medscape Medical News. Available at http://www.medscape.com/viewarticle/810151. Accessed: September 11, 2013.

  20. Dempsey E, McCreery K. Local anaesthetic eye drops for prevention of pain in preterm infants undergoing screening for retinopathy of prematurity. Cochrane Database Syst Rev. 2011 Sep 7. 9:CD007645. [Medline].

  21. Repka MX, Hardy RJ, Phelps DL, et al. Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol. 1993 May. 111(5):618-20. [Medline].

  22. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011 Jan. 118(1):176-83. [Medline].

  23. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17. 364(7):603-15. [Medline].

  24. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Arch Ophthalmol. 1990 Oct. 108(10):1408-16. [Medline].

  25. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003 Dec. 121(12):1684-94. [Medline].

  26. Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol. 1994 Feb. 112(2):154-6. [Medline].

  27. Phelps DL. Retinopathy of prematurity: an estimate of vision loss in the United States--1979. Pediatrics. 1981 Jun. 67(6):924-5. [Medline].

  28. Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol. 2006 Jan. 124(1):24-30. [Medline].

  29. Reynolds JD, Hardy RJ, Kennedy KA, et al. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N Engl J Med. 1998 May 28. 338(22):1572-6. [Medline].

  30. Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1993 Feb. 100(2):230-7. [Medline].

  31. Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006 Feb. 117(2):572-6. [Medline].

  32. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000 Feb. 105(2):295-310. [Medline].

  33. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984 Aug. 102(8):1130-4. [Medline].

  34. Fang JL, Sorita A, Carey WA, Colby CE, Murad MH, Alahdab F. Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis. Pediatrics. 2016 Mar 9. [Medline].

  35. Eldweik L, Mantagos IS. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity. Semin Ophthalmol. 2016. 31 (1-2):163-8. [Medline].

  36. Cao JH, Wagner BD, McCourt EA, Cerda A, Sillau S, Palestine A, et al. The Colorado-retinopathy of prematurity model (CO-ROP): postnatal weight gain screening algorithm. J AAPOS. 2016 Feb. 20 (1):19-24. [Medline].

  37. Shah PK, Prabhu V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of prematurity: Past, present and future. World J Clin Pediatr. 2016 Feb 8. 5 (1):35-46. [Medline]. [Full Text].

 
Previous
Next
 
Retinopathy of prematurity consultation form and fundus drawing.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.